Procept BioRobotics Corporation (PRCT)

NYSE · Broad Market

Latest Move · 2026-02-24

+1.32%
Holds steady ahead of rescheduled Q4 earnings report tomorrow

PROCEPT BioRobotics announced updated dates for its fourth quarter 2025 earnings conference call and investor day due to travel disruptions caused by inclement weather. The company will report financial results after market close on Wednesday, February 25, 2026, with a conference call beginning at 4:30 p.m. Eastern Time. The in-person investor day event has been rescheduled to Thursday, February 26, 2026, at NASDAQ Headquarters in New York City starting at 8:00 a.m. Eastern Time. Live webcasts of both events will be available on the company's investor relations website, with archived recordings available for at least 90 days. TD Cowen maintained a Buy rating on PROCEPT BioRobotics with a target price of $50. The stock rose 1.3 percent following these announcements.

Read full analysis

Previous Move

+2.85%
Gains ahead of rescheduled Q4 earnings as TD Cowen reiterates Buy
2026-02-24

Frequently Asked Questions

Why did Procept BioRobotics Corporation stock move today?

PROCEPT BioRobotics announced updated dates for its fourth quarter 2025 earnings conference call and investor day due to travel disruptions caused by inclement weather. The company will report financial results after market close on Wednesday, February 25, 2026, with a conference call beginning at 4:30 p.m. Eastern Time. The in-person investor day event has been rescheduled to Thursday, February 26, 2026, at NASDAQ Headquarters in New York City starting at 8:00 a.m. Eastern Time. Live webcasts of both events will be available on the company's investor relations website, with archived recordings available for at least 90 days. TD Cowen maintained a Buy rating on PROCEPT BioRobotics with a target price of $50. The stock rose 1.3 percent following these announcements.

What does Procept BioRobotics Corporation do?

Procept BioRobotics develops robotic surgical systems for urological procedures, most notably its HYDROS platform for treating benign prostatic hyperplasia (BPH) via Aquablation therapy. The company has posted revenue growth exceeding 40% year-over-year, with Q3 2025 revenue of $83.3 million and fiscal 2026 guidance of $410-$430 million. The stock trades near its 52-week low heading into Q4 earnings Wednesday after close, with an Investor Day at Nasdaq headquarters the following day.

AI-generated analysis · Not financial advice · Always do your own research
Disclaimer & Terms · Privacy Policy